# NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

> **NCT04984811** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **NeoImmuneTech** · enrollment: 83 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Non-Small Cell Lung Cancer
- Non-Small Cell Lung Carcinoma
- Nonsmall Cell Lung Cancer
- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** efineptakin alfa
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04984811
- **Lead sponsor:** NeoImmuneTech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-03
- **Primary completion:** 2024-09
- **Final completion:** 2025-03
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2024-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04984811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04984811, "NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04984811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*